EMA Authorised: Rolufta Ellipta (previously Rolufta) (umeclidinium bromide) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

EMA authorised Rolufta Ellipta (umeclidinium bromide) for pulmonary disease including chronic obstructive pulmonary disease (COPD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Rolufta Ellipta (umeclidinium bromide)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 04/08/2026